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We have developed a high content 384-well, image-based assay to estimate the effect of compound
treatment on Trypanosoma cruzi amastigotes in 3T3 ﬁbroblasts. In the same well, the effect of compound
activity on host cells can also be determined, as an initial indicator of cytotoxicity. This assay has been
used to identify active compounds from an in-house library of compounds with either known biological
activity or that are FDA approved, and separately, from the Medicines for Malaria Venture Malaria Box
collection. Active compounds were screened against T. cruzi trypomastigotes, utilising an assay devel-
oped with the viability dye resazurin. Twelve compounds with reconﬁrmed solid sample activity, with
IC50 values of less than 10 mM and selectivity indices to T. cruzi amastigotes over 3T3 host cells of between
>22 and 319 times were identiﬁed from these libraries. As 3T3 cells are contact inhibited, with limited
proliferation in the assay, selective compounds of interest were proﬁled in a separate assay to estimate
the viability of compound treated, replicating HEK293 cells. Selective compounds that were not previ-
ously reported in the literature were further proﬁled by extending the incubation time against amasti-
gote infected 3T3 cells to determine if there were residual amastigotes post-treatment, important for the
consideration of the exposure time required for further biological characterisation. The assay develop-
ment process and the suitability of identiﬁed compounds as hit molecules for Chagas disease research
are discussed.
© 2015 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chagas disease, caused by infection with the parasite Trypa-
nosoma cruzi, is endemic to regions of Central and South America
and estimated to cause 12,000 deaths per year (PAHO/WHO,
2015). The acute stage of the disease can go undiagnosed, how-
ever in many cases there is still morbidity and mortality (Teixeira
et al., 2006). In the second, chronic stage, parasitism and inﬂam-
mation of the heart and large colon can result in severe physio-
logical effects, including megacolon and heart disease (Corbett
et al., 2001; Rassi et al., 2000). Ten to 30% of individuals with a
chronic stage infection develop cardiomyopathy leading to con-
tractile dysfunction (Rassi et al., 2000) which may progress toInstitute for Drug Discovery,
Don Young Road, Nathan,
s).
Ltd on behalf of Australian Society fsudden cardiac death (Rossi et al., 2010). There are 2 compounds
that are currently used to treat Chagas disease, the nitro-
heterocyclic compounds benznidazole (BZ) and nifurtimox (NFX).
There is some disagreement in the reported effectiveness of the
use of these drugs to treat the chronic stage of the disease and
both have associated toxicity (Castro et al., 2006). There was hope
with some azole antifungal drugs that have undergone/are un-
dergoing clinical trials for treatment of the chronic phase disease.
However, there have been failures in clinical trials with pos-
aconazole (Molina et al., 2014) and preliminary data from phase II
clinical trials suggests E1224 (the pro-drug of ravuconazole) has
less efﬁcacy than BZ (Moraes et al., 2014). Based on the problems
with current treatments and high failure rate of compounds in
clinical trials, it is essential that new compounds that are active
against T. cruzi are identiﬁed and evaluated for their potential to
progress through the drug discovery pipeline.
The reported activity of compounds against the T. cruzi parasite
has primarily been determined using either target-based oror Parasitology. This is an open access article under the CC BY-NC-ND license (http://
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beneﬁt of exposing the whole organism and thus all targets and
biological pathways to the compounds being tested. Phenotypic
assays available for screening compounds against T. cruzi have
been outlined in a recent review, including the preliminary
application of an image-based approach we have developed to
estimate compound activity against the amastigote form of the
parasite (Sykes and Avery, 2013). More recently there has been an
increase in reported image-based technologies using single ﬂuo-
rescent dye systems, such as the DNA markers DRAQ5™ (Alonso-
Padilla et al., 2015) and DAPI (Neitz et al., 2015). Here we outline
the development of an image-based assay to determine the effect
of compounds against T. cruzi amastigotes, which is also capable of
estimating the toxicity of compounds on host cells. The number of
infected cells, over 7 ﬁelds per well, is estimated utilising a two
dye system to accurately detect the borders of the cytoplasmic
area of the host cell, a method not previously reported for deter-
mining compound activity against the parasite. A separate assay
was also developed to identify compounds with activity against
the trypomastigote form of the parasite measured by the redox
indicator PrestoBlue. As the drugs that are currently used clinically
to treat T. cruzi possess anti-trypomastigote activity (Faundez
et al., 2005), it would be beneﬁcial for new compounds to also
exhibit anti-trypomastigote activity, however not entirely
essential.
Both assays were optimised to be within the limits of detec-
tion of each screening technology. Important factors in the
developmental process of the amastigote assay included deter-
mination of the growth (and life cycle) of the parasite and host in
a 384-well plate, DMSO and drug sensitivity and script develop-
ment that allowed for a reproducible and sensitive determination
of the number of infected cells. Utilising application of the sta-
tistical measurement, the Z0-factor (Zhang et al., 1999), these
assay formats have been shown to be reproducible. Collectively,
these assay formats were considered ideal for screening com-
pound libraries against T. cruzi for early drug discovery
application.
To identify compounds with anti-T. cruzi activity, and to vali-
date the image-based assay, an in-house library of 741 com-
pounds, comprised of both FDA approved compounds and
compounds with previously identiﬁed biological activity was
screened against T. cruzi amastigotes. Repurposing of FDA
approved compounds has been a recurring theme during recent
years for many research areas and libraries containing known
biological and FDA approved compounds have been proﬁled in T.
cruzi phenotypic screens (Sykes and Avery, 2013). The Medicines
for Malaria Venture (MMV) Malaria Box is a collection of 400
chemically diverse compounds comprised of 200 ‘probe-like’ and
200 ‘drug-like’ molecules with activity against the asexual form of
the malaria parasite, Plasmodium falciparum (Spangenberg et al.,
2013). This library has recently been screened against other pro-
tozoan parasites including T. cruzi, in a colorimetric, reporter
gene-based assay (Kaiser et al., 2015). There have been examples
of compounds that share activity across these parasites that could
suggest common targets (Mishina et al., 2007; Ibrahim et al.,
2011). Molecules with known anti-malarial activity may there-
fore represent an excellent starting point for identifying new
chemical scaffolds with anti-trypanosomal activity. The outcomes
of proﬁling a prototype of this library and the in-house library
against T. cruzi are outlined. Selected compounds which did not
clear all parasites from host cells at the maximum effect (Emax)
concentration were further proﬁled in vitro to determine if an
extended incubation increased compound efﬁcacy. The develop-
ment and application of these assays to identify compounds for
early drug discovery are discussed.2. Materials and methods
2.1. Maintenance of T. cruzi parasites
T. cruzi Tulahuen strain epimastigotes were provided by Pro-
fessor Frederick Buckner (the University of Washington, USA).
Trypomastigotes were induced by differentiation of parasites to
metacyclic trypomastigotes in an artiﬁcial triatomine urine
(Contreras et al., 1985). 3T3 host cells (mouse embryo ﬁbroblast;
ATCC CCL92) were maintained in RPMI (Life Technologies, CA, USA)
with no phenol red, supplemented with 10% FCS (growth medium).
Before infectionwith T. cruzi trypomastigotes, 3T3 cells were added
to 25 cm2 ﬂasks at 4  105 cells/ﬂask in growth medium with
100 IU/mL penicillin/streptomycin, and incubated for 24 h at 37 C
and 5% CO2. Trypomastigotes, from the supernatant of a previously
infected culture of 3T3 cells, were added at a multiplicity of infec-
tion (MOI) of 10:1 trypomastigotes: host cells. Following 24 h in-
cubation, trypomastigotes that had not infected host cells were
washed off 3 times with PBS and replaced with fresh medium.
Following 72 h further incubation, trypomastigotes released from
the host cells were collected from the supernatant, centrifuged at
3000 g for 8 min, and diluted to either inoculate a new culture, or
add to plates for assays.
2.2. Infection of 3T3 ﬁbroblasts over 7 days in a 384-well plate
3T3 host cells in 50 mL of growth medium supplemented with
100 IU/mL penicillin/streptomycin were added to a 384-well
collagen I coated plate (CellCarrier, Perkin Elmer, WA, USA), at
1  103 cells/well. After 24 h, 10 mL of trypomastigotes were added
towells and incubated for 24 h before washing off 3 times with PBS.
Based on the growth of 3T3 cells in-plate, it was estimated that host
cells double between 0 and 24 h and the MOI for the addition of
parasite to host cells was calculated accordingly. Parasites were
added at MOI values of 10, 5 and 2:1 parasite to host cell. Parasites
were enumerated at 3, 4, 5, 6 and 7 days of co-culture to assess the
release of trypomastigotes. Infected host cells were counted
following staining with Giemsa. Two wells per parasite concen-
tration were enumerated to estimate infection, by scoring the
number of infected cells per 200 host cells in a well.
2.3. Assay development to detect compound activity on T. cruzi
amastigotes in 3T3 ﬁbroblasts using the Operetta and Opera image-
based systems
2.3.1. Script development and DMSO sensitivity
Host cells were added to plates at a density of 1  103 cells/well
in 50 mL of medium and half the plate was infected with a MOI of
10:1 parasite to host cell, in 10 mL of medum. To the other half, 10 mL
of medium was added. Following 24 h incubation, parasites were
washed off three times with PBS. To determine the DMSO tolera-
bility of the cells, DMSO ranging from a ﬁnal concentration of
1.60%e0.0002% was added in 5 mL of water. Three replicates of each
dilution series were added to both infected and non-infected cells.
Plates were incubated for 48 h, medium was removed and wells
were washed before the addition of 20 mL of 4% paraformaldehyde.
After 15 min incubation at room temperature, 20 mL of 0.01 mg/mL
Hoechst 3342 (Invitrogen, USA), diluted in RPMI, containing 0.1%
Triton X-100 (Sigma Aldrich, St Lois, MO, USA) were added and
incubated for 30 min. Following, 0.05 mg/mL HCS CellMask Green™
(Invitrogen, USA) diluted in RMPI was added and incubated for
30 min. After a ﬁnal wash, 20 mL of RPMI containing 100 IU/mL
penicillin/streptomycin was added. Images were captured on an
Operetta imaging system (PerkinElmer, Waltham, MA, USA), on the
Hoechst 3342 and Alexa Fluor 488 channels, at 20magniﬁcation.
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the Operetta Imaging system Harmony Software (PerkinElmer,
USA). It was determined, by eye, which parameters within the
building blocks best deﬁned ﬁrstly a host cell nucleus, secondly a
host cell cytoplasm, and ﬁnally spot detection script to identify
amastigotes within the host cell. Two and 3 ﬁelds per well were
read and the Z0-factor was calculated. This estimation was
compared to the percentage of cells determined from staining
infected wells with Giemsa and manually counted.
2.3.2. Automated liquid handler for HTS application
To optimise the assay format such that it was amenable to HTS,
it was necessary to remove non-infected parasites, without
disruption to the host cell layer. Additions of parasite and host
cells to 384-well plates were made with a Multidrop liquid
handler (Thermo Scientiﬁc, USA). Following 24 h infection, me-
dium was removed from plates in a PC2 biosafety cabinet by
inverting the plate into a plastic reservoir, followed by the addition
of 50 mL of PBS with a Multidrop liquid handler. The volume was
removed again by inverting the plate. Two wash steps were then
undertaken on a Bravo liquid handler (Agilent, USA), by addition
and removal of 50 mL of PBS. A 384-well, polypropylene plate
(Corning, NY, USA) containing one third puromycin (8.26 mM) in
water, a third NFX (3.28 mM) in 100% DMSO and a third DMSO
(100%) was prepared, with 128 wells per compound/DMSO. This
plate was diluted 1:21 in water in a clear, sterile plate (BD Bio-
sciences, Franklin, NJ, USA) and 5 mL was added to the cell plate.
The ﬁnal concentrations in the assay were 30 mM, 12 mM and 0.37%
for puromycin, NFX and DMSO respectively in the assay and this
plate was used to calculate the Z0-factor. The concentrations of
compounds and DMSO were based on a ﬁnal volume of 65 mL, as
following washes on the Bravo liquid handler, there was 10 mL of
PBS remaining in wells. Following 48 h incubation, wells were
stained and analysed on the Operetta imaging system. The script,
taking images from either 3, 4 or 5 ﬁelds per well were compared.
The percentage infection and the number of infected cells per well
were examined.
2.3.3. Relationship of the MOI versus infected cells on the Operetta
imaging system
The linearity of the number of infected cells in relation to the
MOI used was determined on the Operetta. A plate containing MOI
values from 40:1 parasite: host cell, down to an MOI calculated to
be 0.312:1, with serial dilutions of 2:1 was prepared and analysed
on the Operetta. There were 32 wells used to estimate infected and
host cells for each MOI value.
2.3.4. Optimisation of the number of ﬁelds read on the Opera
imaging system using a 5:1 MOI
Using the Assay Language Interface on the Opera confocal im-
aging system (PerkinElmer, Waltham, MA), the same protocol that
was used to deﬁne infected host cells on the Operetta was applied.
The only difference that 2 stacks per ﬁeld of view (differing in a
height of 2e4 mm), were taken and combined as some amastigotes
appeared to be out of focus in one plane. For both imagers, the
“building block” style in the analysis software allow for the same
criteria to be applied to stained wells. Two plates were prepared
containing infected 3T3 cells, with a third puromycin, NFX and
DMSO. Using the same script as the Operetta imaging system, it was
determined that imaging 5 ﬁelds per well did not result in a Z0-
factor greater than 0.5, nominally used as the cut off to deﬁne good
assay reproducibility (Zhang et al., 1999). A comparison of repro-
ducibility from images taken from 5 to 7 ﬁelds per well were made.
To determine if the identiﬁcation of 5 amastigotes per cell was
sufﬁcient to reduce background spots from the spot analysis script,images taken from 7 ﬁelds in 64 infected wells were analysed and
compared to the same number of non-infected cells using criteria
varying from1 spot per cell to5 spots per cell as a cut off for the
detection of an infected cell. The same wells were analysed for ¼1,
3, 4, 5, 6e10,11e20, 21e30, 31e50, 51e100 and101 spots per host
cell.
2.3.5. Relationship of the MOI to infected cells on the Opera imaging
system
One 384-well plate, containing MOI values ranging from 40:1
parasite: host cells, with 16 wells per treatment, to a MOI calculated
to be 0.078:1 was processed and analysed on the Opera imaging
system. Serial dilutions of 2:1 were prepared. There were 32 wells
for each treatment used to estimate the number of infected host
cells.
2.3.6. Optimised T. cruzi amastigote assay
Additions of parasite and host cells were made with a Multi-
drop plate dispenser (Thermo Scientiﬁc, Newington, NH, USA).
3T3 host cells were seeded into 384-well collagen coated plates
(PerkinElmer, Waltham, MA, USA) at 1  103 cells/well in 50 mL of
growth medium supplemented with 100 IU/mL penicillin/strep-
tomycin. For the primary screening of compound libraries, 2  104
trypomastigotes per well were added in 10 mL of growth medium
supplemented with 100 IU/mL penicillin/streptomycin, and plates
were incubated for a further 24 h. This was equivalent to a 10:1
MOI parasite: host cells, considering that host cells approximately
double over 24 hours. For determination of IC50 values, the con-
centration used was a 5:1 MOI, as assay linearity was improved in
terms of the relationship between the MOI and the resultant
number of host cells infected. This did not affect the sensitivity of
the assay, in terms of the activity of reference compounds (see
section 3, primary screening versus retest). To remove trypo-
mastigotes that had not infected host cells the well volume was
emptied into a reservoir containing a small volume of bleach
solution, replaced with 50 mL of PBS and the well volume was
removed again. Wells were washed twice on a Bravo liquid
handler and 50 mL of growth medium supplemented with 100 IU/
mL penicillin/streptomycin was replaced. Compounds in DMSO
were pre-diluted 1:21 in water with a Minitrack liquid handler
(PerkinElmer, USA) and 5 mL of this volume was added to assay
plates. Plates were incubated for 48 h before ﬂuorescent markers
were added on the Bravo liquid handler. Wells were washed twice
before the addition of 20 mL of 4% paraformaldehyde and incu-
bated for 15 min at room temperature. Twenty mL of 0.01 mg/mL
Hoechst 3348, diluted in RPMI with no FCS, containing 0.1% Triton
X-100 was added and plates were incubated for 30 min. Wells
were washed twice and 20 mL of 0.05 mg/mL HCS CellMask
GreenTM in RMPI with no FCS was added, and incubated for
30 min. After washing, 20 mL of RPMI, no phenol red, containing
100 IU/mL penicillin/streptomycin was added. Plates could be
stored up to 1e2 weeks at 4 C prior to imaging.
Images were taken on an Opera High Content Imager, or an
Operetta High Content imager. On the Opera, images were taken
over seven positions in the well, with 2 stacks (differing in a
height of 2 mm) per well position, whilst on the Operetta, 5 ﬁelds
per well were imaged. For each ﬁeld, one image was taken at
405 nm excitation 450/50 nm emission to capture the Hoechst
stained nuclei, and another at 488 excitation and 540/75 emis-
sion to capture the HCS CellMask Green stained cytoplasm of the
host cell. On the Opera, images were combined and analysed
with the Assay Language Interface software and on the Operetta,
images were analysed using Harmony. Firstly each script identi-
ﬁed the host cell nucleus using the Hoechst image, by size
exclusion of the parasite nuclei. The cytoplasm of the host cell
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nuclei appear as spots within the host cell cytoplasm and were
detected by spot analysis. Host cells containing 5 spots were
considered to be infected.
2.4. Trypomastigote assay: development and optimised assay
format
The development and optimised protocol for the trypomastigote
assay are outlined in the Supplementary Section (Figures S1eS2).
2.5. Screening of a chemical collection of compounds either FDA
approved or with known biological activity
The compound collection was sourced from a variety of sup-
pliers by in-house expert analysis of known drugs and compounds
shown to have biological activity. The FDA compounds contained
within the library are used for the treatment of a variety of in-
dications, including antibacterials, antifungals, antipsychotics, anti-
HIV and anticancer compounds. Compound stocks in 100% DMSO
were stored in the Compounds Australia library facility (www.
compoundsaustralia.com.au), housed within the Eskitis Institute
for Drug Discovery. Concentrations of compounds in the library
collection ranged between 1.7 and 23.1 mM in 100% DMSO. Com-
pounds were screened in three doses in the amastigote assay, at the
neat dose, and at 1:10 and 1:100 of the neat dose. Compounds
displaying greater than 80% activity at the highest screening dose,
with greater than 50% activity at a 1:10 dilution were retested on
the Operetta image-based system, and in the trypomastigote assay.
Compoundswere retested in 15 point doses in duplicate, over N of 2
experiments, at a MOI of 5:1. Compounds considered active
(<10 mM IC50 value) and selective (SI of >10) estimated at the
highest dose screened) were purchased as solids for IC50 value
determination. IC50 values of solid compound stock were deter-
mined from N of 4 experiments.
The positive control used to calculate activity against the host
cells was puromycin, whilst for the amastigotes was NFX. The
reproducibility, measured as the Z0-factor, was determined each
time the assay was run, by including a plate containing a third ﬁnal
concentration of 0.37% DMSO, a third NFX at a ﬁnal concentration of
12 mM and a third puromycin at a ﬁnal concentration of 30 mM.
2.6. MMV Malaria Box primary screening
The Avery lab received a pilot collection, consisting of 685
compounds for evaluation. Dilution of stocks in DMSO were pre-
pared at 5, 2.5 and 1.25 mM, to make ﬁnal assay concentrations of
18.3, 9.2 and 4.6 mM and each plate was screened in duplicate. The
positive controls were NFX and puromycin, whilst the negative
control was 0.37% DMSO.
2.6.1. Retest of DMSO samples
Compounds exhibiting activity of >50% in duplicate at a ﬁnal
concentration of 18.3 mM,with associated activity of >50% at 9.2 mM
were selected for retest in dose response to determine IC50 values. A
separate group was also retested, with >50% activity exhibited at
18.3 mM, with single point, or no corresponding activity at 9.2 mM.
Some compounds appeared to come out of solution in water at the
highest dose of 18.3 mM, the initial dose for retesting compounds
was reduced to 9.2 mM. Compounds were cherry-picked from 5mM
stocks in 100% DMSO and diluted in DMSO, to a working concen-
tration of 2.5 mM. Compounds were diluted into 15 doses in 384-
well plates (Axygen, USA), before dilution into water prior to
addition in the assay. The ﬁnal assay concentrations ranged from
9.2 mM to 0.0002 mM. Compounds were retested in twoindependent experiments. Image capture and analysis was under-
taken on the Operetta image-based system, at 20 magniﬁcation.
Compounds that were considered active had an IC50 value of
<10 mM, and if the IC50 could be determined against 3T3 cells, with
a SI >10. If the IC50 value against 3T3 cells could not be determined,
the SI was calculated by dividing the highest dose of 3T3 cells in the
assay screened by the IC50 value of the compound against T. cruzi
amastigotes.2.6.2. Activity of resourced solid compounds
MMV666080 was purchased from Asinex (Winston-Salem, NC,
USA), and MMV001230, MMV665909 and MMV665914 were pur-
chased from Ambinter (Orleans, France). All of the probe-like
compounds were purchased from Ambinter, except for
MMV665941, which was purchased from Specs (Zoetermeer, The
Netherlands). Compounds were prepared as 20 mM stocks in 100%
DMSO, and diluted into a total of 15 doses in DMSO, ranging from a
ﬁnal concentration of 73 mMe0.002 mM in the amastigote assay,
except for MMV666080, of which the highest concentration was
36.6 mM, due to poor solubility in DMSO at higher concentrations.
Compounds were tested for activity in two independent experi-
ments, in the amastigote and trypomastigote assays. NFX was used
as a positive control to calculate the activity of compounds against
both the trypomastigote and amastigote forms of T. cruzi and pu-
romycin served as a positive control for 3T3 host cells. Compounds
that were considered active had an IC50 value of <10 mM, and if SI
was estimated at >10.2.7. Residual amastigotes following compound treatment
At the Emax concentration, some amastigotes remained in host
cells following 48 h treatment of T. cruzi infected ﬁbroblasts with
the azole antifungal, clotrimazole. Separately, the activity of the
more clinically relevant antifungal compound, posaconazole
(Molina et al., 2014) was determined against T. cruzi amastigotes,
over 48 and 72 h, by increasing the incubation time and staining
with the same ﬂuorescent markers as in the amastigote image-
based assay. As some parasites had already egressed from the
host cells, plates were washed ﬁve times before staining with
ﬂuorescent dyes, to ensure in non-treated wells that the level of
interference (with egressed parasite) was minimal. Posaconazole
was screened in dose over N of 2 experiments, and the plateau of
activity (maximum % inhibition, or Emax) was assessed for the
presence of amastigotes. This same investigation was applied to
MMV665914, MMV665994 and MMV001239.2.8. Activity of selective compounds against HEK293 cells
The activity of CPX and the actives from the MMV library were
determined against human embryonic kidney (HEK293) cells, over
2 independent experiments. A 30 mM concentration of puromycin
was used as a positive control. Cells were harvested and diluted in
high glucose DMEM supplemented with 10% FCS and 100 IU/mL
penicillin/streptomycin, to a concentration of 7.27  104 cells/mL.
Fifty ﬁve microlitres of cells were added to black, clear bottomed
384-well lidded plates (BD Biosciences, USA) with a Multidrop
liquid handler. Cells were incubated for 24 h before the addition of
5 mL of diluted compounds, with a Minitrak liquid handler, and
plates were incubated for 48 h. Ten microlitres of a ﬁnal concen-
tration of 70 mM resazurin (Life Technologies, USA) was added to
wells and plates were incubated for 3 h at 37 C and 5% CO2, before
reading on an Envision plate reader (PerkinElmer, USA) at an
excitation of 530 nm and an emission of 595 nm.
M.L. Sykes, V.M. Avery / International Journal for Parasitology: Drugs and Drug Resistance 5 (2015) 215e228 2192.9. Activity of CPX against sub-conﬂuent 3T3 cells
3T3 cells were plated at concentrations between 1000 cells per
well and 62 cells per well in 384-well collagen coated plates and
incubated for 48 h. Plates were then treated in the same manner as
described for the amastigote assay. The well volume was removed
and wells were washed twice using the Bravo liquid handling
system, before replacing a total volume of 50 mL of growthmedium.
A dose response series of CPX was added to the plate, in duplicate,
for each cell concentration. A positive control of 30 mM of puro-
mycin and negative control of 0.37% DMSOwere added. Following a
further 48 h incubation, ten microlitres of a ﬁnal concentration of
70 mMof resazurinwere added to wells and incubated for 3e6 h. By
examining the relationship of the ﬂuorescent signal to time, it was
determined that following 4 h incubation, the resulting ﬂuorescent
signal was estimated to be within the linear range of detection for
cell concentrations, except for 62 cells/well, which resulted in a
poor signal. The IC50 value of CPX was therefore determined
following 4 h incubation with resazurin and compared for 62, 125
and 1000 cells/well. The IC50 value of puromycin was also deter-
mined at these concentrations. Data was averaged from duplicate
experiments.
3. Results
3.1. Infection of 3T3 ﬁbroblasts over 7 days in a 384-well plate
Parasites cultured in 384-well plates began to egress from host
cells 4 days after host cell infection, with expanded numbers of
parasites seen on day 5. On day 4 there were 4.15  105, 1.82  105
and 4.25  104 trypomastigotes/mL detected in the medium, from
host cells infected with a MOI of 10:1, 5:1 and 2:1, respectively
(Fig. 1A). There was a noticeable difference between the number of
released parasites in the supernatant, both amastigotes and try-
pomastigotes, relative to the MOI used (Fig. 1A and B). There was an
increase in the number of infected cells over time, with themajority
of host cells infected on the seventh day after infection (Fig. 1C).
Due to the release of parasites following 4 days post infection, theFig. 1. Growth of T. cruzi parasites in co-culture with 3T3 ﬁbroblasts in 384-well collagen I co
in the supernatant and (C) the percentage of infected 3T3 ﬁbroblasts, from a co-culture of 3
counts taken from the supernatant of duplicate ﬂasks prepared for each MOI.estimation of the number of infected cells was difﬁcult following 7
days, as released/differentiated amastigotes observed from Giemsa
staining remained on the surface of the plate at all of the MOI
values tested. Hence, to deﬁne an infected cell, those host cells
containing groups of 5 or more parasites, close to one another and
within the host cell were estimated to be infected. There were no
parasites released 3 days post infectionwith the MOI's investigated
in these studies.
3.2. Assay development to detect compound activity on T. cruzi
amastigotes in 3T3 ﬁbroblasts using Operetta and Opera image-
based systems
3.2.1. Script development and DMSO sensitivity
Each of the nuclear analysis building blocks available in the
Harmony software interface were applied to the images of the
cells and the script that best deﬁned a host cell was determined.
This was undertaken by eye. The Harmony software contains four
separate scripts that deﬁne the nucleus of a cell, with cut offs that
can be applied to the size, splitting factors to split one nucleus
from another and contrast to sort identiﬁed nuclei based on the
ﬂuorescent intensity. The numbers to deﬁne criteria used in many
of these script building blocks are arbitrary to the system and a
process of applying each separately and visualising the deﬁned
objects was applied. In effect, the user “teaches” the system to
deﬁne the object of interest. This process was repeated for
detection of the cytoplasm. Spot analysis was optimised by
comparing infected and non-infected host cells. Fig. 2 depicts the
result of spot detection of T. cruzi parasites within the host cell and
how this is visually able to separate parasite nuclei from host cell
nuclei. Table 1 shows each of the building blocks, and the condi-
tions that were applied within each building block of the Harmony
analysis software to detect an infected cell. As there was a level of
background with spot analysis in the non-infected cells, the script
was modiﬁed such that 5 spots per cell deﬁned an infected cell.
This approach reduced the non-speciﬁc background detection, and
thus was utilised for selection of infected cells. The number of host
cells were identiﬁed in each well by exporting the number ofated plates following 3e7 days post infection. (A) trypomastigotes and (B) amastigotes
T3 and T. cruzi in a 384-well plate. Data represents the mean and standard deviation of
Fig. 2. Analysis to determine a T. cruzi infected cell on the Operetta imaging system using building blocks in Harmony software. (A) Overlay of Hoechst and HCS CellMask Green
ﬂuorescent stains (B) Detection of the nucleus of host cells (C) Spot detection to deﬁne a parasite (one amastigote ¼ 1 spot). (D) Expanded section of (C) to show the effectiveness of
spot detection in identifying parasites within the host cell. P ¼ parasite nucleus; H ¼ Host cell nucleus. Scale bars represent 20 mm. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
Table 1
Function of the methods within the ﬁnd region building blocks on the Opera and Operetta imaging systems contained within the amastigote assay script. The parameters used
within the developed script to identify parasites within host cells are shown for each building block of nuclear, cytoplasm and spot analyses.
Find region (method) Method Function Parameters available Parameter used
Nuclei (C) Roundness Estimates the roundness of the detected nuclei 2 to 3 0.6
Common threshold The lower level of pixel intensity for the whole image that may
belong to nuclei
0e1 0 (no constriction)
Area Estimates the area of the detected nuclei 100 to 200 80
Cytoplasm (A) Common threshold Parameter determining ﬁrst guess borders of the cytoplasm 0e1 0 (no constriction)
Cytoplasm (A) Select cell region Tuning the inner border, from nuclear to cell border 200 to 100 50
Spot detection (C) Radius Determines the radius of radius of spot-like features 0e55 2.2
Contrast Determines how intense a spot must be to be detected 0e1 0.13
Spot to region intensity Sets a lower threshold for spot to cell intensity. The ratio of the spot peak
intensity to the mean intensity of the cell region that is searched.
0e10 1.6
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and cytoplasm that were co-localised. The number of infected cells
was also exported, as those host cells that contained 5 spots
within the cytoplasm.
When infected cells were enumerated with 2 ﬁelds per well, the
Z0-factor was below 0.5, considered to be the cut-off to determine a
robust assay (Zhang et al., 1999). Increasing the number of ﬁelds
imaged per well to 3 increased the number of cells detected and
improved the Z0-factor. The number of infected cells was
184 ± 0.658 and there were 582 ± 10.4 host cells, identiﬁed from
infected wells. Therefore a mean of 31.6% cells were detected as
infected by the criteria set. Giemsa staining of wells and manual
counting of infected cells resulted in an estimated infection rate of
32.4%, conﬁrming the precision of the Operetta script to identify T.
cruzi infected cells. From an evaluation of wells containing non-
infected cells, there were 539 ± 2.73 host cells. In non-infected
cells, there were 3.92 ± 1.36 infected cells per well, detected us-
ing the script, thus displaying a low background from the spot
analysis employed.The potential impact of DMSO on both the host cells and para-
sites was investigated. A slight effect was observed on the number
of host cells and consequently the number of parasites identiﬁed,
when DMSO concentrations  0.8% were used (Fig. 3). Activities
calculated at this dose, relative to non-infected cells, were
18.90 ± 4.90% and 25.94 ± 5.84% for detected parasites and host
cells, respectively. Similarly there was an effect observed on host
cells in non-infected wells, with an activity of 21.9 ± 7.20% observed
with the addition of 0.8% DMSO.
3.2.2. Automated liquid handler for HTS application
By adjusting the pipette tips to ensure that they were as close as
possible to the plate surface, some host cells were removed from
the plate surface. However, by increasing the plate height, all of the
trypomastigotes were not removed. A manual wash step was
included, to compensate for the inability of the automated liquid
handler to remove the whole well volume. Following automated
steps, capturing 3 ﬁelds per well resulted in a Z0-factor of 0.49, close
to the cut off of 0.5. By increasing the number of ﬁelds imaged per
Fig. 3. The effect of DMSO concentration on (A) T. cruzi amastigotes in 3T3 host cells (B) total host cells detected using an Operetta image-based reader and Harmony analysis
software. The percent activity was calculated in reference to wells containing no parasite. Error bars represent the standard deviation of measurements, from triplicate doses over
two replicate plates, from one experiment.
Fig. 4. The number of captured images per well of T. cruzi infected 3T3 cells and the resulting parasite and host cell numbers and assay reproducibility on the Operetta. (A) number
of infected cells and host cells and (B) the Z0- factor based on the number or percent of infected cells, or total host cells. 384 ewell plates were analysed on the Operetta imaging
system, at 20 magniﬁcation. Error bars represent the standard deviation of measurements, calculated from 128 wells, over one experiment.
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statistically relevant and thus the Z0-factor was improved, to 0.55
(Fig. 4). A mean infection of 32.26 ± 5.46% per well was determined
using this approach, from 2 independent experiments.
3.2.3. Linearity of the assay using the Operetta image-based system
Using automated methods, the linearity of the assay was
assessed, by infecting host cells with varying MOI's. Host cells
containing differentiated trypomastigotes caused some loss of
linearity at higher concentrations as the cells were not detected by
the script as efﬁciently, due to trypomastigotes being tightly
compact and not as amenable to spot detection. This was most
noticeable at a 40:1 MOI. It is probable that the maximum number
of infected cells may also be achieved at these MOI values (66%Fig. 5. The linearity of the relationship between the MOI and the resulting number of T. cr
Operetta and Opera image-based systems. (A) at 20e40:1 MOI, there appears to be a maximu
of 5:1 parasite to host cell. Representative data is from one experiment, with 28 wells perestimated at both 20:1 and 40:1 MOI). The linearity for both the
Opera and Operetta image-based systems are shown in Fig. 5.
3.2.4. Development of the assay on the Opera image-based system
The developed T. cruzi amastigote/host cell assay was optimized
on the Opera Image-based system. The use of the Opera was un-
dertaken to allow a more efﬁcient high-throughput analysis of
plates, with the ability to use more than one reader at a time, and
this instrument is able to use an automated arm to read plates. Five
or 7 ﬁelds within each well were imaged and compared on the
Opera, as it was discovered that when images were taken from 5
ﬁelds per well, there was 60% less cells identiﬁed than on the
Operetta. The ﬁeld of view (FOV) is different between these imaging
systems, although the camera size is the same. The FOV using a 20uzi infected 3T3 ﬁbroblasts per well following 48 h post infection, determined on the
m number of host cells infected (B) a linear relationship was found up to a multiplicity
MOI. R2 ¼ 0.99.
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using 20 magniﬁcation on the Operetta is 675 509 mm2, a dif-
ference of 43% between the machines. Therefore the difference in
the FOV contributed to the difference in the host cell numbers
observed. By increasing the number of ﬁelds taken per well to 7, the
number of identiﬁed host cells was increased, therefore improving
the reproducibility of the results obtained, resulting in a Z0-factor of
0.59 ± 0.01 for the amastigote assay and 0.81 ± 0.06 for detection of
the 3T3 host cells.
A criteria of 5 spots per host cell cytoplasm was used to
identify a T. cruzi amastigote infected cell. To determine whether
the identiﬁcation of5 amastigotes per well was sufﬁcient to lower
or remove these background spots, images from 7 ﬁelds in one well
were analysed with a cut-off of 5 spots to a minimum of 1 spot
per cell. Fig. 6A shows that when a cut off of 1 parasite was used,
that there was detection of infected cells in non-infected wells
(91.25 ± 11.25 cells/well). This was conﬁrmed by determining the
number of infected cells in non-infected wells containing just one
spot (70.21 ± 9.48 infected cells/well) (Fig. 6B). Increasing the cut
off to 5 spots/cytoplasm decreased the number of infected cells
per well to 1.57 ± 1.46 cells/well, without signiﬁcantly decreasing
the number of infected cells, in comparison to 4 spots per cell
(Fig. 6B). Fig. 7 shows the ﬁnal assay format as depicted on the
Opera image-based system.3.2.5. Relationship of the MOI to the number of infected cells on the
Opera imaging system
The linearity of infection was retested on the Opera, using the
conditions outlined as for the Operetta. This conﬁrmed that the
assay detection was linear, with respect to the number of infected
cells per well, up to a 5:1 MOI. The linearity of the assay on both the
Opera and Operetta image-based system are shown in Fig. 5.3.3. Determination of the activity of a library of FDA approved
compounds and compounds with known biological activity
Twenty seven compounds were re-screened in dose response,
with 15 dilutions prepared from the neat dose, ranging from a
ﬁnal assay concentration of 16.1e29.7 mM, over N of 2 experi-
mental replicates. 100% of compounds re-conﬁrmed activity at
the highest screening concentration, and 56% (15) of these
compounds re-conﬁrmed activity at the mid-dose. Six azole an-
tifungals with selectivity against T. cruzi identiﬁed from this li-
brary have previously been reported (Sykes and Avery, 2013). We
have included one azole antifungal, clotrimazole herein as an
example of this class of compound and retested the activity from
a fresh solid sample. The activity against the amastigote, host cell
and trypomastigote, with the SI for each compound in relation toFig. 6. The number of spots used as a cut off to deﬁne a T. cruzi amastigote infected cell, usin
cell (B) Criteria used determined how many cells were detected as infected between ¼1 tothe amastigote to host cell are shown in Table 2, for 5 compounds
which displayed an IC50 value of <10 mM against amastigotes.
Solid samples of the compounds clotrimazole, ciclopirox olamine
(CPX), camptothecin (Sigma Aldrich, USA) and clemastine fuma-
rate (Sapphire Biosciences, Ann Arbor, MI, USA) were screened in
dose response in the trypomastigote and amastigote assays, and
the IC50 values against both parasite life cycle stages were esti-
mated. The IC50 values for the reference compounds NFX and
puromycin are shown in Table 2. The Z0-factor was greater than
0.5 for all of the plates tested. A one way ANOVA, undertaken in
Prism 6.0 revealed that there was no signiﬁcant difference in the
IC50 values of the reference compounds NFX and puromycin
determined for both primary and retest screening campaigns
(P < 0.05).3.4. Malaria Box primary screening
Of 685 compounds tested, there were 10 compounds which
exhibited >50% activity, in duplicate at 18.3 mM, with a corre-
sponding activity of >50% at 9.2 mM in the T. cruzi amastigote assay.
From the second group of compounds selected for retest, there
were 13 compounds with >50% activity exhibited at 18.3 mM, with
<50% activity displayed at 9.2 mM. The IC50 value of NFX against T.
cruzi amastigotes was 0.764 mM, with no corresponding activity
against host cells. Puromycin demonstrated an IC50 value against T.
cruzi amastigotes of 2.35 mM and 2.29 mM against host cells.3.4.1. Malaria Box retest
Of those compounds that were retested, 11 displayed an IC50
value against T. cruzi, with selectivity toward the parasite. Seven of
these compounds were probe-like, and two of these were two
batches of the same compound, MMV665594. Two compounds did
not have a classiﬁcation attributed to them in theMMVMalaria Box
library. The identity of these compounds was determined in Pub-
Chem (https://pubchem.ncbi.nlm.nih.gov/search/search.cgi), by
searching for the batch code. These compounds were STK700023,
the azole antifungal clotrimazole, and STL088556, 9-aminoacridine,
N0-(acridin-9-yl)-N,N-dimethylbenzene-1,4-diamine. Of the
remaining compounds, MMV665941 also displayed activity against
the trypomastigote (Table 3). As clotrimazole was already identiﬁed
from the in-house library, results are not shown here. Four com-
pounds were drug-like. Of these compounds, IC50 values ranged
from 0.46 mM to 2.25 mM, with estimated SI values ranging from
>4.09 to >19.9. Two of these compounds, MMV666080 and
MMV665909 were also active against the trypomastigote life cycle
form (Table 4). Compounds were re-tested as solid samples and all
of the compounds reconﬁrmed as active, except for the compound
STL088556 (Tables 2 and 3).g the Opera image-based system. (A) Criteria used were 1, 2, 4, 5 spots per host
101 spots per host cell cytoplasm.
Fig. 7. Identiﬁcation of T. cruzi infected 3T3 cells using the Opera QEHS high-content imaging system. Images were taken at 20 water magniﬁcation. (A) infected host cells. Green
represents the host cell cytoplasm detected with HCS CellMask Green. Blue depicts nuclear material from both host cells and parasite stained with Hoechst. (B) Deﬁnition of the
cytoplasmic region of host cells in which spot detection of parasite nuclei is undertaken. (C) Spot detection to deﬁne parasite nuclei. (D) Application of script using the Opera assay
language interface to deﬁne infected cells. Infected cells are green, red are non-infected. (EeH) follows the same deﬁnitions for (AeD), only that these are infected host cells that
have been treated with 12 mM NFX for 48 h. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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CPX, from the in house library and the 8 activeMMV compounds
were tested against HEK293 cells. CPX displayed an IC50 value ofTable 2
Active compounds identiﬁed from a library containing compounds with known biologi
trypomastigotes and the host cell 3T3. Classiﬁcations refer to compounds reported as acti
(SI) of compounds refers to (the IC50 value of compounds against 3T3 ﬁbroblasts, if attaina
against the amastigote form of T. cruzi). Bold type represents activity of re-sourced solid sa
values are from testing compounds from the compound library, stored in DMSO, over
compounds were puromycin and NFX.
Compound Structure Amastigote IC50 ± std
Antifungals
Clotrimrazole HCl 0.19 ± 0.04
0.17 ± 0.12
Ciclopirox Olamine 5.37 ± 0.51
3.90 ± 3.00
Other compounds
Clemastine Fumarate 0.76 ± 0.22
0.29 ± 0.14
Camptothecin 0.34 ± 0.00
0.09 ± 0.02
Sodium Mycophenolate 0.90 ± 0.003b1.4 ± 1.07 mM, therefore representing a selectivity index (SI) of 0.36
(Table 2). MMV665941, MMV666080 and MMV665909 displayed
activity against HEK293 cells, also resulting in selectivity indexes of
<10, indicating that these compounds may have toxicity issues.cal activity/are FDA approved compounds, against Trypanosoma cruzi amastigotes,
ve against speciﬁc diseases or are FDA approved as a treatment. The selectivity index
ble, or if not the highest dose tested against 3T3 cells)/(the IC50 value of compounds
mples of compound, tested in 4 independent experiments. The remainder of the IC50
2 independent experiments. NT ¼ not tested. SD ¼ standard deviation.* Control
ev (mM) Host IC50 ± stdev (mM) SI (3T3) Trypomastigote activity
NA at 16.5 mM >86.84 NA at 19.5 mM
19% at 18.3 mM >107.65 NA at 21.6 mM
53% at 19.0 mM >3.54 0.90 ± 0.22
42% at 136.5 mM >35.0
0.36a
1.00 ± 0.49
NA at 21.6 mM >28.42 80% at 25.5 mM
48% at 18.3 mM >63.10 48% at 21.6 mM
44% at 16.8 mM >49.41 NA at 19.9 mM
38% at 5.0 mM >55.56 NA at 5.9 mM
30% at 17.2 mM >19.11 NA at 20.3 mM
(continued on next page)
Table 2 (continued )
Compound Structure Amastigote IC50 ± stdev (mM) Host IC50 ± stdev (mM) SI (3T3) Trypomastigote activity
Control drugs
*Nifurtimox 0.69 ± 0.09 32% at 153.1 mM 221.88 0.95 ± 0.33
0.81 ± 0.39 30% at 127.5 mM >157.41 1.15 ± 0.46
*Puromycin 3.14 ± 0.17 3.04 ± 0.52 0.97 0.62 ± 0.09
1.58 ± 1.44 2.76 ± 0.69 1.75 0.56 ± 0.03
SI ¼ selectivity index to 3T3 host cells. Activities in bold ¼results for solid sample. For the reference compounds, stock was always prepared from solid stock. Bold in this case
refers to the activity of these compounds during retest of solid stocks of active compounds.
a Selectivity index (SI) to HEK293 cells.
b Sodium mycophenolate was not tested as a solid sample.
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The IC50 value of CPX was determined for 3T3 cells at seeding
densities of 1000, 250 and 125 cells per well. CPX displayed activityTable 3
The activity of probe-like compounds from the MMV Malaria Box against Trypanosoma c
with no classiﬁcation. The selectivity index (SI) of compounds is the highest dose tested
cruzi. (1) two batches of the same compound. Data is from two independent experimen
Compound name Structure T. cruzi amastigote IC50
(mM ± SD)
3T3% activity
(mM ± SD)
MMV665941 (crystal/
gentian violet)
0.09 ± 0.04 88% at 9.2 mM
0.23 ± 0.06 83% at 73.3 m
MMV665994 0.66 ± 0.70
0.95±0.0051
NA at 9.2 mM
1.23 ± 0.61 NA at 73.3 mM
MMV001239 0.86 ± 0.006 NA at 9.2 mM
3.55 ± 2.36 NA at 73.3 mM
MMV001241 1.34 ± 0.00884 NA at 9.2 mM
2.32 ± 0.66 NA at 73.3 mM
*STL088556 2.37 ± 1.51 30% at 9.2 mM
62% at 73 mM 62% at 73.3 m
SI ¼ selectivity index to 3T3 host cells. Stated for solid samples of compound. a: Select
compound were identiﬁed in the library. Activities in bold ¼ results for solid sample. For
case refers to the activity of these compounds during retest of solid stocks of active com
Selectivity is based on the activity of solid samples.
* Compounds with no classiﬁcation.
NA ¼ not active.
NT ¼ not tested.
a Selectivity (SI) of T. cruzi amastigotes to HEK293 cells.of 38% at 73 mM using a seeding density of 1000 cells per well and
IC50 values of 5.98 ± 1.0 mM and 3.23 ± 0.485 mM with seeding
densities of 250 and 125 cells per well, respectively. Puromycin
exhibited an IC50 value against host 3T3 cells at a density ofruzi amastigotes, trypomastigotes, the host cell, 3T3 and HEK293 cells. *Compounds
against 3T3 host cells/the IC50 value of compounds against the amastigote form of T.
ts. SD ¼ standard deviation.
highest dose or IC50 IC50 HEK293
(mM ± SD)
IC50 T. cruzi Trypomastigote
(mM ± SD)
SI (3T3)
NT 0.84 ± 0.13 >318.7
>6.52aM 1.50 ± 0.73 1.60 ± 0.237
NT NA at 10.9 mM >59.59
>64.55a
NA at 79.4 mM 52% at 87 mM
NT NA at 10.9 mM >20.65
>22.37aNA at 79.4 mM NA at 87 mM
NT NA at 10.9 mM >31.59
>34.22a44% at 79.4 mM 87% at 87 mM
NT 65% at 10.9 mM NA
NAaM 115% at 79.4 mM 8.88 ± 0.212
ivity (SI) of T. cruzi amastigotes to HEK293 cells 1. Duplicate samples of the same
the reference compounds, stock was always prepared from solid stock. Bold in this
pounds.
Table 4
The activity of drug-like compounds from the MMV Malaria Box against Trypanosoma cruzi amastigotes, trypomastigotes, the host cell, 3T3 and HEK293 cells. Bold type
represents activity of re-sourced solid samples of compound. All other activities relate to compounds stored in 100% DMSO. Solid samples of the compound were also tested
against HEK293 as a secondarymeasurement of cytotoxicity. The selectivity index (SI) of compounds refers to (the IC50 value of compounds against 3T3 ﬁbroblasts, if attainable,
or if not the highest dose tested against 3T3 cells)/(the IC50 value of compounds against the amastigote form of T. cruzi). NA ¼ not active. NT ¼ not tested. SD ¼ standard
deviation. *Control compounds were puromycin and NFX.
Compound
name
Structure T. cruzi amastigote IC50
(mM ± SD)
3T3% activity highest dose or IC50
(mM ± SD)
IC50 HEK293
(mM ± SD)
IC50 T. cruzi Trypomastigote
(mM ± SD)
SI (3T3)
MMV001230 0.46 ± 0.01 NA at 9.2 mM NT NA at 10.8 mM >87.26
>94.52a0.84 ± 0.17 NA at 73.3 mM NA at 79.4 mM 96% at 86.5 mM
MMV666080 0.69 ± 0.79 40% at 9.2 mM NT 0.90 ± 0.06 >25.77
2.03a1.42 ± 0.99 34% at 36.6 mM 2.88 ± 0.90 0.52 ± 0.04
MMV665909 1.02 ± 0.88 35% at 9.2 mM NT 1.08 ± 0.01 >56.82
1.53a1.29 ± 0.13 44% at 73.3 mM 1.97 ± 0.65 1.05 ± 0.13
MMV665914 2.25 ± 0.31 25% at 9.2 mM NT NA at 10.8 mM >42.37
>45.90a1.73 ± 0.19 NA at 73.3 mM NA at 79.4 mM 65% at 86.5 mM
*Puromycin 2.54 ± 0.13 3.39 ± 0.28 NT 0.505 ± 0.0849 1.48
0.12a2.26 ± 0.03 3.35 ± 0.12 0.28 ± 0.04 0.44 ± 0.63
*NFX 0.59 ± 0.10 NA% at 127.5 mM NT 1.09 ± 0.433 >231.8
>251.1a0.55 ± 0.02 NA% at 127.5 mM NA at 138.1 mM 1.25 ± 0.01
SI ¼ selectivity index to 3T3 host cells. Stated for solid samples of compound.
Activities in bold ¼ results for solid sample. For the reference compounds, stock was always prepared from solid stock. Bold in this case refers to the activity of these
compounds during retest of solid stocks of active compounds.
NA ¼ not active.
NT ¼ not tested.
Selectivity is based on the activity of solid samples.
a Selectivity (SI) of T. cruzi amastigotes to HEK293 cells.
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and 3.49 ± 0.64 mM using 250 and 125 cells per mL, respectively.3.7. Residual amastigotes following compound treatment
Following 48 h incubation with clotrimazole, there were
amastigotes that appeared to remain at the Emax concentration of
this compound (Figure S3). To determine if this was the case for a
clinically relevant compound with activity against T. cruzi, the ac-
tivity of the antifungal compound posaconazole was determined
against T. cruzi amastigotes, following 48 and 72 h exposure. To
identify activity following 72 h exposure, parasites were stained
and analysed using the same protocol outlined for the 48 h image-
based assay. As some parasites had egressed from cells, there were
released trypomastigotes and amastigotes that were not contained
within host cells, however the script was able to estimate infected
cells (Figure S4). There was no change in the IC50 value of pos-
aconazole between 48 and 72 h, estimated to be 0.006 ± 0.0006 mM
following 48 h exposure and 0.0049 ± 0.0036 mM following 72 h.
Although there was a decrease in the total number of infected cells,not all parasites were removed from host cells, with 76% and 94%
inhibition following 48 and 72 h incubation, respectively. The
presence of a small number of amastigotes could be seen following
treatment with an Emax of 50 nM (Figure S5), whereas no parasites
were seen following 48 or 72 h treatment with 12 mM NFX.
Prioritised compounds from the Malaria Box, MMV665914,
MMV665994 and MMV001239 were incubated in a dose series for
both 48 and 72 h and residual spots within host cells at the Emax
concentration of compounds (estimated at 18 mM) were scored.
MMV665914 and MMV665994 removed 97% of infections at 18 mM
following 48 h incubation and MMV001239 removed 90%. In each
case, by eye there were small populations of what appeared to be
amastigotes that could be seen. Following 72 h incubation, both
MMV665914 and MMV665994 removed 99% of parasites and
MMV001239 removed 96%.4. Discussion
From the studies undertaken, the successful development of a
sensitive, 384-well image-based assay to estimate compound
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3T3 host cells has been developed and optimised. Factors that were
considered to be important to the reproducibility and reliability of
the application of this assay included determination of the parasite
life cycle in a 384-well plate, DMSO sensitivity, wash steps to
remove trypomastigotes post-infection and script development to
minimise the false detection of amastigotes utilising a spot analysis
based algorithm. During investigation of the life cycle of parasites
in-plate, following 7 days incubation post-infection, there were a
signiﬁcant number of amastigotes on the surface of the plate, even
following washing out of the medium. As parasites began to egress
4 days post infection, this allowed for an assay to extend to 3 days
from the addition of trypomastigotes. Compound exposure
following wash off of trypomastigotes was therefore for a total of
48 h. Other authors have used 72 h incubation of T. cruzi infected
cells with compounds in image-based formats, although thesewere
utilising different strains of T. cruzi and host cells, and the parasite
life cycle in the plate was not reported (Engel et al., 2010; Alonso-
Padilla et al., 2015; Moraes et al., 2014).
The DMSO tolerability of the amastigote assay was determined,
important for the optimal health of the parasite and host cells
during compound incubation. The maximum concentration of
DMSO tolerated by T. cruzi amastigotes and 3T3 ﬁbroblasts at a MOI
of 10:1 parasite: host cell was 0.37% DMSO, with 0.43% DMSO not
affecting the viability of trypomastigotes (results not shown). Both
assays developed demonstrated a linear relationship between the T.
cruzi trypomastigote inoculum and the resulting detection of par-
asites. The linearity of detection was optimised for each assay,
resulting in a Pearson correlation coefﬁcient of determination (R2)
of 0.99 for the detection of parasite infected 3T3 cells; and
trypomastigotes.
The minimal detection of amastigotes on the Opera image-
based system was deﬁned, imperative to reducing false spot
detection, or background, that could result in an over estimation of
infected cells. It is of importance to be able to deﬁne small numbers
of parasites within host cells following compound treatment, as
surviving parasites could continue the infective cycle. From
screening an in-house library, it was determined that the azole
antifungal, clotrimazole, exhibited low efﬁcacy at the Emax against T.
cruzi amastigotes following 48 h incubation. Posaconazole, a com-
pound that has recently failed to show efﬁcacy in clinical trials
against the chronic phase of Chagas (Molina et al., 2014), was
subsequently tested over 48 and 72 h treatment of T. cruzi infected
cells and also failed to remove the whole parasite population, with
76% and 94% of parasites removed from host cells, respectively. This
could be due to the fact that several cell divisions are required
before inhibition and cell death occur with CYP51 treatment of T.
cruzi (Neitz et al., 2015). Posaconazole has been recently shown to
similarly be sub-efﬁcacious at high concentrations in vitro utilising
the DNA marker DRAQ5 to identify Tulahuen strain parasites in
U2OS cells following 96 h treatment, in which parasites were
reduced by 93% (Moraes et al., 2014). Posaconazole also only
reduced Y strain infection to 84% following 72 h exposure and
approximately 60% after exposure to 80 nM of compound for 48 h
(Moraes et al., 2014). Both image-based assays highlight this effect,
which had not previously been reported with image-based or re-
porter gene methods to identify T. cruzi infection in vitro. This
emphasises the importance of using sensitive methods, with time-
course exposures to investigate the efﬁcacy of compounds. A
beneﬁt of identifying this sub-efﬁcacious effect is that slow-acting
compounds could be de-prioritised in screening campaigns if there
are faster acting/more effective compounds. Also, the T. cruzi drug
discovery pipeline is well populated with CYP51 inhibitors (Pena
et al., 2015), which could promote de-prioritisation of this chemi-
cal class of compound. The image-based assay however could beused to screen a combination of (sub-efﬁcacious) inhibitors such as
posaconazole with other active compounds, to identify if there is a
synergistic effect of compound action (Fügi et al., 2015). A medic-
inal chemistry effort could potentially improve efﬁcacy, dependent
upon if it were an intrinsic target problem or could be overcome, as
other factors such as solubility may also cause this effect.
From the in-house library that was proﬁled, non-antifungal
compounds that were identiﬁed from initial screening against
amastigotes, with an IC50 value of <10 mM and demonstrated
selectivity, were sodium mycophenolate, clemastine fumarate and
camptothecin. Immunosuppressive therapy with mycophenolate,
used for heart transplants for patients with chronic Chagas disease,
has been associated with an increase in reactivation of the disease
therefore leading to a high risk with this compound (Bestetti et al.,
2007, Campos et al., 2008, Marchiori et al., 2007). Camptothecin
was identiﬁed as a lead against T. cruzi some years ago (Bodley and
Shapiro 1995), however poor solubility, rapid inactivation and
cytotoxicity which has been shown for this compound in human
trials as an anticancer drug candidate, have hindered its further
development (Li et al., 2006). Clemastine fumarate has recently
been identiﬁed in the literature as active against T. cruzi however
failed to show activity in an in vivomodel of acute infection (Planer
et al., 2014). There were a number of other antihistamines, both
ﬁrst and second generation (21 in total, results not shown) also
screened in this library and there were no others that were active
against T. cruzi in the amastigote assay. This compound may have a
novel mode of action against T. cruzi amastigotes in vitro and in the
future, identiﬁcation of this target may warrant further investiga-
tion. The activity of these compounds highlights the ability of the
assay to identify compounds that have historically shown activity
against T. cruzi, supporting the use of this assay to proﬁle com-
pounds against the parasite.
The non-azole antifungal, CPX, showed novel activity against T.
cruzi with an IC50 value of 3.9 mM against T. cruzi amastigotes and
1 mM against trypomastigotes following the retest of solid sample.
However, this compound displayed activity against HEK293 cells
and sub-conﬂuent 3T3 cells, detected with resazurin. The mode of
action against host cells may therefore be related to cell division/
metabolism and potential toxicity remains an issue for this com-
pound. This highlights the beneﬁt of the use of proliferation assays
when considering compound activity against infected, contact
inhibited cells or non-dividing cells such as macrophages. Com-
pounds that effect replication or cell multiplication for instancewill
not be detected by exposure to differentiated THP1 cells (Siqueira-
Neto et al., 2012). Here, activity against 3T3 cells stands as an initial
determination of cytotoxicity. In drug discovery programs, it is
common to employ a panel of mammalian cells when considering
the potential toxicity of a compound (Sarver et al., 2012). This is
particularly important in Chagas disease, whereby the safety and
tolerability of current drugs is an issue.
Of those compounds determined to be active from the MMV
Malaria Box collection screened, MMV001230, MMV665909,
MMV001241 andMMV666080 have recently been identiﬁed as hits
against T. cruzi (Kaiser et al., 2015). An in vitro assay was used to
proﬁle the activity of Malaria Box, in which the parasite used to
infect cells was transfected with a b-galactosidase reporter gene,
and activity was assessed utilising a colorimetric readout. There
were similar levels of activity for a majority of common compounds
estimated by both assays although notably, MMV666080 was less
active in the image-based assay against T. cruzi amastigotes
(1.42 mM versus <0.13 mM in the reporter gene assay). Differences
between the results obtained for this compound may be related to
the increased time of incubation and therefore also the T. cruzi life
cycle stages exposed, as there are 7 days incubation post infection
in the b-galactosidase assay. There may also be a differential effect
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This is always a consideration when comparing different assay
formats. MMV666080, MMV665909; and also MMV665941 were
found to be active against HEK293 cells and similar to CPX, could
have an effect against cell division/other mammalian cells which
supports the use of the estimation of cytotoxic effects to prioritise
compounds.
There were three selective compounds, MMV665914,
MMV665994 and MMV001239 that were identiﬁed here that
remain as hit compounds for further investigation. Reported bio-
logical activity, along with those of related substructures, were
identiﬁed in SciFinder (http://www.cas.org/products/sciﬁnder).
MMV665914, 4-chloro-N-(2-(4-(2-methoxyphenyl)piperazin-1-
yl)-2-(pyridin-3yl) ethyl) benzene sulfonamide returned no
related literature or similar substructures. Based on the phenyl
piperazine structure embedded within this molecule, it could
possess ion channel agonism or antagonism properties (Martin,
1985; Swanson et al., 2005), although the presence of a pyridyl
moiety could also suggest that this may inhibit CYP51, as pyridine
containing compounds have been shown previously to be active
against T. cruzi CYP51 (Chen et al., 2009; Hargrove et al., 2013).
However, 97% of parasites were removed following 48 h incubation
(at 18 mM), and 99% at 72 h, suggesting this compound was more
efﬁcient than the CYP51 inhibitors posaconazole and clotrimazole
at reducing the parasite load from host cells. MMV665994, 3-(3,3-
Dichloro-2-propen-1-yl)-2-methyl-4(1H)-quinolinone, is a
quinolinone-based compound, with two similar substructures re-
ported in the literature, of which onewas a potential suppressant of
inhibition of bacterial lysozymes (Voet et al., 2011). The lack of
other speciﬁc target-based publications for this class of compound
does not necessarily support this as a mode of action. MMV001239,
4-cyano-N-(5-methoxy-1,3-benzothiazol-2-yl)-N-(pyridin-3-
ylmethyl)benzamide is not reported in publications in relation to
biological activity. As there was no cytotoxicity detected against
either 3T3 or HEK 293 cells, this compound could be investigated
further. Considering the pyridyl motif contained within this
compound, it could again be possible that this is a CYP51
inhibitor. Ninety percent of infected cells were removed following
48 h and 96% were removed following 72 h incubation, therefore
this compound is most likely slow acting, although more
efﬁcacious at the Emax than posaconazole and clotrimazole after a
48 h incubation period in vitro.
The image-based assay described is reproducible and has been
successful in identifying a number of compounds that have already
been reported in the literature with activity against T. cruzi,
describing the sensitivity of this format. In addition to this, the
assay has the advantage of determining the presence of low levels
of amastigotes following compound treatment, important for the
potential pharmacological consideration of compounds. We are
currently investigating viability probes and wash off assays to
determine if these remaining amastigotes are viable. Alongside
supporting the use of this assay to proﬁle the activity of compounds
against T. cruzi, we also report those compounds that can be
considered for further biological and chemical proﬁling.
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